Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - September 19, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

AC Immune completes Recruitment for Low-Dose Cohort of Participants in World's First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer's Disease-like Characteristics in Individuals with Down Syndrome. Phase 1 b study of AC Immune's ACI-24, the first anti-amyloid vaccine for treatment of Alzheimer's disease-like characteristics in...
9/12/17 - Achillion Stock Tumbles At Termination Of Hepatitis Collaboration [The Hartford Courant]
Sept. 12 Shares of Achillion Pharmaceuticals Inc. tumbled 22 percent Monday after Janssen Pharmaceuticals Inc. informed the New Haven company it was ending its license and collaboration arrangement on hepatitis C. Janssen, one of the Janssen Pharmaceutical Companies of Johnson& Johnson, announced it's discontinuing its investigational hepatitis C
9/12/17 - Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced positive results from a Phase 2 a clinical trial of topical ocular ADX-102 in patients with dry eye disease. "ADX-102 is a promising agent fo
9/12/17 - Allergan`s Patent Loophole Could Be a Huge Gift for Pfizer [T-break Tech (Middle East)]
On Friday, Allergan announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. There`s at least one other potential winner: Pfizer. The Saint Regis Mohawk Tribe approached Allergan about the possibility of transferring ownership of the patents for Restasis several weeks ago.
9/12/17 - BioPharmX Announces Preliminary Data from Rosacea Feasibility Study
BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, is announcing preliminary data from a feasibility study of BPX-01 to assess the safety and efficacy of topical minocycline gel at both the 1% and 2% doses for the treatment of rosacea. The preliminary data from the ongoing study suggest good tolerability and promis
9/12/17 - Biotech Stocks on Investors' Radar PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences
On Monday, September 11, 2017, US markets saw broad based gains with all sectors finishing the trading sessions in green. This Tuesday morning, looks at the performance of these four Biotechnology stocks: PDL BioPharma Inc., Progenics Pharmaceuticals Inc., Agenus Inc., and Aptose Biosciences Inc.. On Monday, shares in Incline
9/12/17 - Cardiome Announces Agreement with Basilea for Distribution of Zevtera/Mabelio (Ceftobiprole) in Europe and Israel
-Cardiome Pharma Corp. today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera / Mabelio . Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34 European countries and Israel. The drug is currently marketed in Germany,
9/12/17 - Cardiome Announces Agreement with Basilea for Distribution of Zevtera/Mabelio (Ceftobiprole) in Europe and Israel
-Cardiome Pharma Corp. today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera / Mabelio . Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34 European countries and Israel. The drug is currently marketed in Germany,
9/12/17 - Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer [All Iraq News Agency (AIN)]
Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to CK-101, the Companys third-generation epidermal growth-factor receptor inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer. Orphan Drug Designation is granted by t
9/12/17 - Chimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory Affairs
Chimerix, a biopharmaceutical company committed to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced the appointment of Heather Knight-Trent, PharmD, as Vice President of Regulatory Affairs. Knight-Trent brings more than 15 years of pharmaceutical regulatory experience to..
9/12/17 - Combine Solicitation - 68 FY18 Radio pharmacy
Office Address: Department of Veterans Affairs; Network Contracting Office 4; WVAMC Wilmington VA Medical Center; 1601 Kirkwood Highway; Wilmington, DE 19805. Description: Department of Veterans Affairs. The Wilmington, Delaware VA Medical Center has a procurement request for radiopharmaceuticals.
9/12/17 - Compounding Pharmacy Market Size, Share And Research Global Industry Trends Report, 2017-2022 | Hexa Reports
Geographically, this report is segmented into several key Regions, with production, consumption, revenue, market share and growth rate of Compounding Pharmacy in these regions, from 2012 to 2022, covering. **North America** Europe** China** Japan** Southeast Asia** India. **Fagron** Wedgewood Pharma** CAPS** Fresenius Kabi** PharMEDium Services** C
9/12/17 - Concurrent treatment with OX40- and PD1-targeted cancer immunotherapies may be detrimental
Journals in Which the Studies were Published: Clinical Cancer Research and Cancer Immunology Research, two journals of the American Association for Cancer Research. Authors: Senior author of the Clinical Cancer Research study: Bernard A. Fox, PhD, Harder Family Endowed Chair for Cancer Research at Providence Cancer Center and chief of the Laborator
9/12/17 - Coronary Stents Market: Pit Falls, Present Scenario and Growth Prospects from 2017 to 2025
San Francisco, CA 09/11/2017 Global Coronary Stents Market: OverviewCoronary stents are used during the treatment of coronary arteries that supply the heart muscle with blood. A tube-shaped device inserted in coronary arteries, they help open up an artery and are left there permanently.Fat often gets deposited along the arterial wall, thereby
9/12/17 - Demand for DrugDev Spark? Soars Among Small Biotechs and Pharma Seeking Best-in-Class Technology for Clinical Trial Planning, Startup and Conduct
DrugDev, a QuintilesIMS company, continues to strengthen its position as the clinical technology provider for small to mid-size biotechs and pharma worldwide with continued adoption of the DrugDev Spark? unified clinical trial suite. DrugDev's growth has come as a result of proven success improving clinical trials across therapeutic areas with sp
9/12/17 - ERYTECH to Present at Morgan Stanley Global Healthcare Conference
ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the 15 th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017 at the Grand Hyatt.
9/12/17 - Expensive Drug Driving Up Medicare Expenditures Without Evidence of Greater Efficacy
Oregon Health and Science University issued the following news release:. Medicare spent more than $1 billion over a five-year period and more than $500 million in 2015 alone on a high-priced drug that has not proved more effective than much less expensive corticosteroids, researchers at OHSU in Portland, Oregon, and the OHSU/Oregon State University
9/12/17 - EyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships
WALTHAM, Mass. EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company focused on developing and commercializing products using two proprietary platform technologies for treating diseases and disorders of the eye, today announced its launch of a social media presence on Facebook, Twitter and LinkedIn. Because the informat
9/12/17 - FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido?; PDUFA Date Set For February 28, 2018
Sorrento Therapeutics, Inc., announced today that SCILEX Pharmaceuticals Inc., a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration acknowledgement of receipt of its recently resubmitted New Drug Application for ZTlido? which has been considered a complete, class 2 response to the prior action letter.
9/12/17 - FDAnews Announces New Management Report Drugmaker's Guide to ASTM E2500: Best Practices for Increasing Process Efficiency and FDA Compliance
FDA investigators want to see that drugmakers understand their products and processes and are implementing procedures properly. Drugmaker's Guide to ASTM E2500 explains the principles of ASTM E2500, uses case studies to show how to best implement it and shows how to use the standard to fulfill FDA expectations. How the standard helps identify criti
9/12/17 - Findings in the Area of Manufacturing Reported from Purdue University (Mitigating the US Drug Shortages Through Pareto-Improving Contracts)
By a News Reporter-Staff News Editor at Journal of Technology New research on Business- Manufacturing is the subject of a report. According to news originating from Indiana, Pennsylvania, by VerticalNews correspondents, research stated, "Drug shortages have been a major challenge facing the US pharmaceutical industry and government in recent year
9/12/17 - GNW-News: Sandoz proposed biosimilar rituximab accepted for review by the FDA (english)
Sandoz proposed biosimilar rituximab accepted for review by the FDA. Novartis International AG/ Sandoz proposed biosimilar rituximab accepted for review by the FDA. *Sandoz believes the comprehensive data package submitted to the FDA for.
9/12/17 - HanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Biologic Therapies in Greater China
SEOUL, South Korea, SHANGHAI and CAMBRIDGE, Massachusetts, Sept. 12, 2017/ PRNewswire/ HanAll Biopharma Co., Ltd. and Harbour BioMed announced today that they have entered into a strategic collaboration and license agreement to develop, manufacture and commercialize in Greater China HanAll's two novel biologics, the anti-FcRn monoclonal antibody,
9/12/17 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 36796) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Vaccines and Related Biological Products Advisory Committee to discuss and make recommendations on the safety and effectiveness of Zoster Vaccine Recombinant, Adjuvanted, manufactured by GlaxoSmithKline Biologicals. LOCATION: FDA White Oak Campus, 10903
9/12/17 - Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer
DURHAM, NC/ ACCESSWIRE/ September 12, 2017/ Heat Biologics, Inc., a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, has been granted a Type C meeting with the U.S. Food and Drug Administration to discuss the registrational pathway for our non-small cell lung cancer trial with HS-110 in combi
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement